Finally, the touchdown PCR and melting conditions of this DPYD HRM assay were suitable for analysis of KRAS, BRAF, and EGFR somatic hotspot mutations in tumor samples (not shown), thus enabling simultaneous analysis of relevant mutations for targeted cancer therapy. Here, EGFR is linked to neoplasm.